Antegren natalizumab: Began Phase III studies

Biogen Inc. (BGEN), Cambridge, Mass. Elan Corp. plc (ELN), Dublin, Ireland Product: Antegren natalizumab Business: Autoimmune/Inflammation Therapeutic category: Immune modulation Target: Integrin a(...